help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Svec, F.
Right arrow Articles by Tate, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svec, F.
Right arrow Articles by Tate, D.

Endocrinology, Vol 125, 3103-3108, Copyright © 1989 by Endocrine Society


ARTICLES

Location of the second steroid-binding site on the glucocorticoid receptor

F Svec, V Teubner and D Tate
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112.

The ability of nonradioactive progesterone to accelerate the dissociation of tritiated dexamethasone from the agonist-binding site of the glucocorticoid receptor was used as a probe for the existence of a second antagonist steroid site. The goal was to evaluate if this second site was on the glucocorticoid receptor and, if so, on what region of that protein. The magnitude of acceleration of dissociation was assessed during purification of the receptor as well as with the untransformed (multimeric), transformed (monomeric), and mero-receptor. In each preparation progesterone caused a statistically significant increase in the rate of agonist dissociation. The documentation of acceleration of dissociation during purification suggests that progesterone one is interacting with a site on the glucocorticoid receptor and not with another protein. Evidence for the second binding site was found using each form of the receptor, untransformed, transformed, and mero-receptor, suggesting that the second binding site resides on the steroid-binding domain of the receptor which is on the carboxy-terminus, topographically close to the agonist-binding site.


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. D. Galigniana, G. P. Vicent, G. Piwien-Pilipuk, G. Burton, and C. P. Lantos
Mechanism of Action of the Potent Sodium-Retaining Steroid 11,19-Oxidoprogesterone
Mol. Pharmacol., July 1, 2000; 58(1): 58 - 70.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
N. Vassiliadou, L. Tucker, and D. J. Anderson
Progesterone-Induced Inhibition of Chemokine Receptor Expression on Peripheral Blood Mononuclear Cells Correlates with Reduced HIV-1 Infectability In Vitro
J. Immunol., June 15, 1999; 162(12): 7510 - 7518.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. J. Modarress, J. Opoku, M. Xu, N. J. Sarlis, and S. S. Simons Jr.
Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity
J. Biol. Chem., September 19, 1997; 272(38): 23986 - 23994.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society